Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 348 participants.

Also called NCT01427920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 348 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01427920
  • EudraCT 2010-024303-27
Other papers using this trial's data
  • The SimpleMix study with biphasic insulin aspart 30: a randomized controlled trial investigating patient-driven titration versus investigator-driven titration Current medical research and opinion, 2014-12 DOI, PubMed 25180608

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, China, India, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01427920. Randomized; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-07 (actual). Results posted on 2013-09-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes
Acronym
SimpleMix™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
biphasic insulin aspart 30
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01427920
Content hash
2a9c47eb24ee75cfb707811c77c853e8def944c6ed2ec3700b313236867d9308